This 2018 short report by Tirelli et al. evaluated the use of oxygen-ozone autohemotherapy (O2-O3-AHT) as a supportive treatment for cancer-related fatigue. Fifty patients with various cancers (breast, lung, colon, renal, prostate, melanoma, hepatocellular carcinoma) received O2-O3-AHT twice weekly for one month, followed by twice-monthly maintenance therapy. Fatigue severity was
